Loading
NASDAQHealthcareBiotechnology
Latest quote
$18.15
+$0.24 · +1.34%
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Previous close
$18.15
+$0.24 · +1.34%
After-hours
$18.15
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Day range
Current $18.15
52-week range
Current $18.15
Regular session · ET · Market data may be delayed.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Day range
Current $18.15
52-week range
Current $18.15
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 66.31M USD |
| Selling, general, and administrative | 20.98M USD |
| Operating expenses | 87.29M USD |
| Interest income | 11.4M USD |
| Depreciation and amortization | 1.41M USD |
| Operating income | −87.29M USD |
| Net income | −74.88M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$43.00
136.91% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.1M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM6.47M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3.97M0.00%95.4B USD0.05%$235+0.80%
AdvisorShares Psychedelics ETFPSIL1.56M3.44%46.85M USD1.84%$21.765+3.69%
Schwab U.S. Small-Cap ETFSCHA1.38M0.01%21.73B USD0.03%$32.79+0.40%
iShares Russell 2000 Growth ETFIWO1.38M0.01%13.97B USD0.24%$356.78+0.94%
ALPS Medical Breakthroughs ETFSBIO1.22M0.65%187.46M USD0.50%$55.04+2.03%
iShares Russell 2000 Value ETFIWN886.72K0.01%13.85B USD0.24%$210.87-0.04%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFAdvisorShares Psychedelics ETFPSILSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
